Finding the big spenders beyond big pharma

Big pharma’s spending power might be unrivalled, but an increasingly muscular group of developers is emerging. Companies like Novo Nordisk, Vertex and Regeneron have significantly upped their R&D bills over the last five years, while others have become active acquirers.